Phenotypes for human respiratory genetics

Respiratory Genetics

Volumn , Issue , 2005, Pages 15-25

  Litonjua, Augusto A ^a   Weiss, Scott T ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 48349123042     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b13341-18     Document Type: Chapter

References (99)

1. Ferris BG, Jr. Epidemieology standardization project. Am Rev Respir Dis 1978; 118: 1-88.
2. Weiss ST, Tager IB, Weiss JW et al. Airways responsiveness in a population sample of adults and children. Am Rev Respir Dis 1984; 129: 898-902.
3. Toelle BG, Peat JK, Salome CM et al. Toward a definition of asthma for epidemiology. Am Rev Respir Dis 1992; 146: 633-7.
4. Standardization of Spirometry, 1987 Update. Statement of the American Thoracic Society. Am Rev Respir Dis 1987; 136: 1285-98.
5. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995; 152: 1107-36.
6. Crapo RO, Casaburi R, Coates AL et al. Guidelines for methacholine and exercise challenge testing - 199. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000; 161: 309-29.
7. Rijcken B, Schouten JP, Weiss ST et al. The relationship between airway responsiveness to histamine and pulmonary function level in a random population sample. Am Rev Respir Dis 1988; 137: 826-32.
8. Marsh DG. Mapping the genes for IgE production and allergy. Adv Exp Med Biol 1996; 409: 43-53.
9. O’Byrne PM, Postma DS. The many faces of airway inflammation: asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: S41-S66.
10. Strieter RM. Mechanisms of pulmonary fibrosis: conference summary. Chest 2001; 120: 77S-85S.
11. Chmiel JF, Berger M, Konstan MW. The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol 2002; 23: 5-27.
12. Kharitonov SA, Barnes PJ. Biomarkers of some pulmonary diseases in exhaled breath. Biomarkers 2002; 7: 1-32.
13. Paredi P, Kharitonov SA, Barnes PJ. Analysis of expired air for oxidation products. Am J Respir Crit Care Med 2002; 166: S31-7.
14. Rahman I, Kelly F. Biomarkers in breath condensate: a promising new non-invasive technique in free radical research. Free Radic Res 2003; 37: 1253-66.
15. Fujitaka M, Kawaguchi H, Kato Y et al. Significance of the eosinophil cationic protein/eosinophil count ratio in asthmatic patients: its relationship to disease severity. Ann Allergy Asthma Immunol 2001; 86: 323-9.
16. Stelmach I, Majak P, Grzelewski T et al. The ECP/Eo count ratio in children with asthma. J Asthma 2004; 41: 539-46.
17. Tang RB, Chen SJ. Serum levels of eosinophil cationic protein and eosinophils in asthmatic children during a course of prednisolone therapy. Pediatr Pulmonol 2001; 31: 121-5.
18. Koller DY. Sampling methods: urine/blood analysis. Am J Respir Crit Care Med 2000; 162: S31-3.
19. Reimert CM, Poulsen LK, Bindslev-Jensen C et al. Measurement of eosinophil cationic protein (ECP) and eosinophil protein X/eosinophil derived neurotoxin (EPX/EDN). Time and temperature dependent spontaneous release in vitro demands standardized sample processing. J Immunol Methods 1993; 166: 183-90.
20. Pronk-Admiraal CJ, Bartels PC. Effect of clotting temperature and eosinophil concentration on the eosinophil cationic protein concentration in serum. Scand J Clin Lab Invest 1994; 54: 185-8.
21. Wempe JB, Tammeling EP, Koeter GH et al. Blood eosinophil numbers and activity during 24 hours: effects of treatment with budesonide and bambuterol. J Allergy Clin Immunol 1992; 90: 757-65.
22. Peterson CG, Enander I, Nystrand J et al. Radioimmunoassay of human eosinophil cationic protein (ECP) by an improved method. Establishment of normal levels in serum and turnover in vivo. Clin Exp Allergy 1991; 21: 561-7.
23. Chae SC, Lee YC, Park YR et al. Analysis of the polymorphisms in eotaxin gene family and their association with asthma, IgE, and eosinophil. Biochem Biophys Res Commun 2004; 320: 131-7.
24. Evans DM, Zhu G, Duffy DL et al. Major quantitative trait locus for eosinophil count is located on chromosome 2q. J Allergy Clin Immunol 2004; 114: 826-30.
25. Tauber E, Herouy Y, Goetz M et al. Assessment of serum myeloperoxidase in children with bronchial asthma. Allergy 1999; 54: 177-82.
26. Eichler I, Nilsson M, Rath R et al. Human neutrophil lipocalin, a highly specific marker for acute exacerbation in cystic fibrosis. Eur Respir J 1999; 14: 1145-9.
27. Morrow JD, Roberts LJ. The isoprostanes: unique bioactive products of lipid peroxidation. Prog Lipid Res 1997; 36: 1-21.
28. Proudfoot J, Barden A, Mori TA et al. Measurement of urinary F(2)-isoprostanes as markers of in vivo lipid peroxidation - A comparison of enzyme immunoassay with gas chromatography/mass spectrometry. Anal Biochem 1999; 272: 209-15.
29. Dworski R, Roberts L J, II, Murray JJ et al. Assessment of oxidant stress in allergic asthma by measurement of the major urinary metabolit of F2-isoprostane, 15-F2t-IsoP (8-iso-PGF2alpha). Clin Exp Allergy 2001; 31: 387-90.
30. Pratico D, Basili S, Vieri M et al. Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2alpha-III, an index of oxidant stress. Am J Respir Crit Care Med 1998; 158: 1709-14.
31. Wood LG, Fitzgerald DA, Gibson PG et al. Lipid peroxidation as determined by plasma isoprostanes is related to disease severity in mild asthma. Lipids 2000; 35: 967-74.
32. Rahman I, Morrison D, Donaldson K, MacNee W. Systemic oxidative stress in asthma, COPD, and smokers. Am J Respir Crit Care Med 1996; 154: 1055-60.
33. Boots AW, Haenen GR, Bast A. Oxidant metabolism in chronic obstructive pulmonary disease. Eur Respir J Suppl 2003; 46: 14s-27s.
34. Bickerman HA, Sproul EE, Barach AL. An aerosol method of producing bronchial secretions in human subjects: a clinical technic for the detection of lung cancer. Dis Chest 1958; 33: 347-62.
35. Pin I, Gibson PG, Kolendowicz R et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax 1992; 47: 25-9.
36. Fahy JV, Boushey HA, Lazarus SC et al. Safety and reproducibility of sputum induction in asthmatic subjects in a multicenter study. Am J Respir Crit Care Med 2001; 163: 1470-5.
37. Jayaram L, Parameswaran K, Sears MR, Hargreave FE. Induced sputum cell counts: their usefulness in clinical practice. Eur Respir J 2000; 16: 150-8.
38. Belda J, Leigh R, Parameswaran K et al. Induced sputum cell counts in healthy adults. Am J Respir Crit Care Med 2000; 161: 475-8.
39. Wilson N. Measurement of airway inflammation in asthma. Curr Opin Pulm Med 2002; 8: 25-32.
40. Nagayama Y, Odazima Y, Nakayama S et al. Eosinophils and basophilic cells in sputum and nasal smears taken from infants and young children during acute asthma. Pediatr Allergy Immunol 1995; 6: 204-8.
41. Twaddell SH, Gibson PG, Carty K et al. Assessment of airway inflammation in children with acute asthma using induced sputum. Eur Respir J 1996; 9: 2104-8.
42. Brightling CE, Ward R, Woltmann G et al. Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma. Am J Respir Crit Care Med 2000; 162: 878-82.
43. Kharitonov SA, Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1693-722.
44. Henriksen AH, Lingaas-Holmen T, Sue-Chu M, Bjermer L. Combined use of exhaled nitric oxide and airway hyperresponsiveness in characterizing asthma in a large population survey. Eur Respir J 2000; 15: 849-55.
45. Kharitonov SA, Yates D, Robbins RA et al. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 1994; 343: 133-5.
46. Persson MG, Zetterstrom O, Agrenius V et al. Single-breath nitric oxide measurements in asthmatic patients and smokers. Lancet 1994; 343: 146-7.
47. Maziak W, Loukides S, Culpitt S et al. Exhaled nitric oxide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 998-1002.
48. Kharitonov SA, Wells AU, O’Connor BJ et al. Elevated levels of exhaled nitric oxide in bronchiectasis. Am J Respir Crit Care Med 1995; 151: 1889-93.
49. Kharitonov SA, Robbins RA, Yates D et al. Acute and chronic effects of cigarette smoking on exhaled nitric oxide. Am J Respir Crit Care Med 1995; 152: 609-12.
50. Rutgers SR, van der Mark TW, Coers W et al. Markers of nitric oxide metabolism in sputum and exhaled air are not increased in chronic obstructive pulmonary disease. Thorax 1999; 54: 576-80.
51. Kharitonov SA, Cailes JB, Black CM et al. Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension. Thorax 1997; 52: 1051-5.
52. Balfour-Lynn IM, Laverty A, Dinwiddie R. Reduced upper airway nitric oxide in cystic fibrosis. Arch Dis Child 1996; 75: 319-22.
53. Thomas SR, Kharitonov SA, Scott SF et al. Nasal and exhaled nitric oxide is reduced in adult patients with cystic fibrosis and does not correlate with cystic fibrosis genotype. Chest 2000; 117: 1085-9.
54. van’s Gravesande KS, Wechsler ME, Grasemann H et al. Association of a missense mutation in the NOS3 gene with exhaled nitric oxide levels. Am J Respir Crit Care Med 2003; 168: 228-31.
55. Wechsler ME, Grasemann H, Deykin A et al. Exhaled nitric oxide in patients with asthma: association with NOS1 genotype. Am J Respir Crit Care Med 2000; 162: 2043-7.
56. American Thoracic Society. Recommendations for standardized procedures for the on-line and off-line measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children-199. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 1999; 160: 2104-17.
57. Kharitonov S, Alving K, Barnes PJ. Exhaled and nasal nitric oxide measurements: recommendations. The European Respiratory Society Task Force. Eur Respir J 1997; 10: 1683-93.
58. Baraldi E, de Jongste JC, European Respiratory Society, American Thoracic Society. Measurement of exhaled nitric oxide in children, 2001. Eur Respir J 2002; 20: 223-37.
59. Holz O, Richter K, Jorres RA et al. Changes in sputum composition between two inductions performed on consecutive days. Thorax 1998; 53: 83-6.
60. Nightingale JA, Rogers DF, Barnes PJ. Effect of repeated sputum induction on cell counts in normal volunteers. Thorax 1998; 53: 87-90.
61. Hunt J. Exhaled breath condensate: an evolving tool for noninvasive evaluation of lung disease. J Allergy Clin Immunol 2002; 110: 28-34.
62. Hunt JF, Fang K, Malik R et al. Endogenous airway acidification. Implications for asthma pathophysiology. Am J Respir Crit Care Med 2000; 161: 694-9.
63. Jobsis Q, Raatgeep HC, Schellekens SL et al. Hydrogen peroxide in exhaled air of healthy children: reference values. Eur Respir J 1998; 12: 483-5.
64. Scheideler L, Manke HG, Schwulera U et al. Detection of nonvolatile macromolecules in breath. A possible diagnostic tool? Am Rev Respir Dis 1993; 148: 778-84.
65. Corradi M, Folesani G, Andreoli R et al. Aldehydes and glutathione in exhaled breath condensate of children with asthma exacerbation. Am J Respir Crit Care Med 2003; 167: 395-9.
66. Corradi M, Rubinstein I, Andreoli R et al. Aldehydes in exhaled breath condensate of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167: 1380-6.
67. Montuschi P, Collins JV, Ciabattoni G et al. Exhaled 8- isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med 2000; 162: 1175-7.
68. Montuschi P, Corradi M, Ciabattoni G et al. Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensation in asthma patients. Am J Resp Crit Care Med 1999; 160: 216-20.
69. Montuschi P, Kharitonov SA, Ciabattoni G et al. Exhaled 8-isoprostane as a new non-invasive biomarker of oxidative stress in cystic fibrosis. Thorax 2000; 55: 205-9.
70. Montuschi P, Ciabattoni G, Paredi P et al. 8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases. Am J Respir Crit Care Med 1998; 158: 1524-7.
71. Carpenter CT, Price PV, Christman BW. Exhaled breath condensate isoprostanes are elevated in patients with acute lung injury or ARDS. Chest 1998; 114: 1653-9.
72. Madani A, Keyzer C, Gevenois PA. Computed tomography assessment of lung structure and function in pulmonary emphysema. In: Bankier A, Gevenois PA (eds). European Respiratory Monograph. Vol. 30, 2004: 145-60.
73. Hoffman EA, McLennan G. Assessment of the pulmonary structure-function relationship and clinical outcomes measures: quantitative volumetric CT of the lung. Acad Radiol 1997; 4: 758-76.
74. Ujita M, Hansell DM. Small airways diseases: detection and insights with computed tomography. In: Bankier A, Gevenois PA (eds). European Respiratory Monograph, Vol. 30, 2004: 166.
75. Bergin C, Muller N, Nichols DM et al. The diagnosis of emphysema. A computed tomographic-pathologic correlation. Am Rev Respir Dis 1986; 133: 541-6.
76. Hruban RH, Meziane MA, Zerhouni EA et al. High resolution computed tomography of inflation-fixed lungs. Pathologic- radiologic correlation of centrilobular emphysema. Am Rev Respir Dis 1987; 136: 935-40.
77. Webb WR, Stein MG, Finkbeiner WE et al. Normal and diseased isolated lungs: high-resolution CT. Radiology 1988; 166: 81-7.
78. Kazerooni EA. Radiologic evaluation of emphysema for lung volume reduction surgery. Clin Chest Med 1999; 20: 845-61.
79. Bankier AA, De Maertelaer V, Keyzer C, Gevenois PA. Pulmonary emphysema: subjective visual grading versus objective quantification with macroscopic morphometry and thin-section CT densitometry. Radiology 1999; 211: 851-8.
80. Gevenois PA, de Maertelaer V, De Vuyst P et al. Comparison of computed density and macroscopic morphometry in pulmonary emphysema. Am J Respir Crit Care Med 1995; 152: 653-7.
81. Mishima M, Hirai T, Itoh H et al. Complexity of terminal airspace geometry assessed by lung computed tomography in normal subjects and patients with chronic obstructive pulmonary disease. Proc Natl Acad Sci USA 1999; 96: 8829-34.
82. Muller NL, Staples CA, Miller RR, Abboud RT. ‘Density mask’. An objective method to quantitate emphysema using computed tomography. Chest 1988; 94: 782-7.
83. Gevenois PA, De Vuyst P, Sy M et al. Pulmonary emphysema: quantitative CT during expiration. Radiology 1996; 199: 825-9.
84. Dirksen A, Friis M, Olesen KP et al. Progress of emphysema in severe alpha-1-antitrypsin deficiency as assessed by annual CT. Acta Radiol 1997; 38: 826-32.
85. Gould GA, MacNee W, McLean A et al. CT measurements of lung density in life can quantitate distal airspace enlargement - an essential defining feature of human emphysema. Am Rev Respir Dis 1988; 137: 380-92.
86. Coxson HO, Rogers RM, Whittall KP et al. A quantification of the lung surface area in emphysema using computed tomography. Am J Respir Crit Care Med 1999; 159: 851-6.
87. Uppaluri R, Mitsa T, Sonka M et al. Quantification of pulmonary emphysema from lung computed tomography images. Am J Respir Crit Care Med 1997; 156:248-54.
88. Nakano Y, Muller NL, King GG et al. Quantitative assessment of airway remodeling using high-resolution CT. Chest 2002; 122: 271S-5S.
89. Amirav I, Kramer SS, Grunstein MM, Hoffman EA. Assessment of methacholine-induced airway constriction by ultrafast highresolution computed tomography. J Appl Physiol 1993; 75: 2239-50.
90. McNitt-Gray MF, Goldin JG, Johnson TD et al. Development and testing of image-processing methods for the quantitative assessment of airway hyperresponsiveness from high-resolution CT images. J Comput Assist Tomogr 1997; 21: 939-47.
91. Nakano Y, Muro S, Sakai H et al. Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function. Am J Respir Crit Care Med 2000; 162: 1102-8.
92. Reinhardt JM, D’Souza ND, Hoffman EA. Accurate measurement of intrathoracic airways. IEEE Trans Med Imaging 1997; 16: 820-7.
93. Wood SA, Zerhouni EA, Hoford JD et al. Measurement of threedimensional lung tree structures by using computed tomography. J Appl Physiol 1995; 79: 1687-97.
94. King GG, Muller NL, Whittall KP et al. An analysis algorithm for measuring airway lumen and wall areas from high-resolution computed tomographic data. Am J Respir Crit Care Med 2000; 161: 574-80.
95. Saba OI, Hoffman EA, Reinhardt JM. Maximizing quantitative accuracy of lung airway lumen and wall measures obtained from X-ray CT imaging. J Appl Physiol 2003; 95: 1063-75.
96. Boulet L, Belanger M, Carrier G. Airway responsiveness and bronchial-wall thickness in asthma with or without fixed airflow obstruction. Am J Respir Crit Care Med 1995; 152: 865-71.
97. Niimi A, Matsumoto H, Amitani R et al. Airway wall thickness in asthma assessed by computed tomography. Relation to clinical indices. Am J Respir Crit Care Med 2000; 162: 1518-23.
98. Brown RH, Mitzner W. Understanding airway pathophysiology with computed tomograpy. J Appl Physiol 2003; 95: 854-62.
99. O’Connor G, Sparrow D, Taylor D et al. Analysis of doseresponse curves to methacholine. An approach suitable for population studies. Am Rev Respir Dis 1987; 136: 1412-7.